Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (Review of TA611) [ID4069]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 12 June 2024
Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy [ID5100]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 21 August 2024
Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Olaparib for maintenance treatment of BRCA-negative platinum-sensitive relapsed ovarian, fallopian tube or primary peritoneal cancer [ID6205]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC